Can stereotactic ablative radiotherapy in early stage lung cancers produce comparable success as surgery?

Thoracic Surgery Clinics

Volumn 23, Issue 3, 2013, Pages 369-381

  Shirvani, Shervin M ^a   Chang, Joe Y ^a   Roth, Jack A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Comparative effectiveness; NSCLC; SABR; SBRT; Stage I

Indexed keywords

ADVERSE OUTCOME; BRACHIAL PLEXUS INJURY; BRONCHUS INJURY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ESOPHAGUS ULCER; INTERMETHOD COMPARISON; LUNG CANCER; LUNG FUNCTION; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PATIENT POSITIONING; PLEURA EFFUSION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIB FRACTURE; SPINAL CORD DISEASE; STEREOTACTIC BODY RADIATION THERAPY; THORAX PAIN; TRACHEA INJURY; TREATMENT OUTCOME;

COMPARATIVE EFFECTIVENESS; NSCLC; SABR; SBRT; STAGE I;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PATIENT SELECTION; PROGNOSIS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; STEREOTAXIC TECHNIQUES;

EID: 84881575089     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2013.05.009     Document Type: Review

References (50)

1. Chang J. Stereotactic ablative radiotherapy for stage I NSCLC: successes and existing challenges. JThorac Dis 2011, 3(3):144-146.
2. Senan S., Palm D., Lagerwaard F. Stereotactic ablative radiotherapy for stage I NSCLC: recent advances and controversies. JThorac Dis 2011, 3(3):189-196.
3. Shirvani S.M., Chang J.Y. Scalpel or SABR for treatment of early-stage lung cancer: clinical considerations for the multidisciplinary team. Cancers 2011, 3(3):3432-3448.
4. Chang J.Y., Roth J.A. Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thorac Surg Clin 2007, 17(2):251-259.
5. Chang J.Y., Dong L., Liu H., et al. Image-guided radiation therapy for non-small cell lung cancer. JThorac Oncol 2008, 3(2):177-186.
6. Liu H., Choi B., Zhang J., et al. Assessing respiration-induced tumor motion and margin of internal target volume for image-guided radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 2005, 63(Suppl 1):S30.
7. Nehmeh S., Erdi Y., Pan T., et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 2004, 31:3179-3186.
8. Rosenzweig K., Hanley J., Mah D., et al. The deep inspiration breath-hold technique in the treatment of inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000, 48(1):81-87.
9. Timmerman R., Paulus R., Galvin J., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303(11):1070-1076.
10. Nagata Y., Takayama K., Matsuo Y., et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63(5):1427-1431.
11. Uematsu M., Shioda A., Suda A., et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001, 51(3):666-670.
12. Xia T., Li H., Sun Q., et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 66:117-125.
13. Stauder M.C., Macdonald O.K., Olivier K.R., et al. Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. Radiother Oncol 2011, 99:166-171.
14. Chang J.Y., Liu H., Balter P., et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol 2012, 7:152.
15. Timmerman R., McGarry R., Yiannoutsos C., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. JClin Oncol 2006, 24(30):4833-4839.
16. Nagata Y., Wulf J., Lax I., et al. Stereotactic radiotherapy of primary lung cancer and other targets: results of consultant meeting of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys 2011, 79(3):660-669.
17. Nagata Y., Hiraoka M., Shibata T., et al. Aphase II trial of stereotactic body radiation therapy for operable TIN0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403). Int J Radiat Oncol Biol Phys 2010, 78:S27.
18. Joyner M., Salter B.J., Papanikolaou N., et al. Stereotactic body radiation therapy for centrally located lung lesions. Acta Oncol 2006, 45(7):802-807.
19. Forquer J.A., Fakiris A.J., Timmerman R.D., et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009, 93(3):408-413.
20. Chang J.Y., Balter P.A., Dong L., et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 72(4):967-971.
21. Lagerwaard F.J., Haasbeek C.J., Smit E.F., et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008, 70(3):685-692.
22. Voroney J.P., Hope A., Dahele M.R., et al. Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. JThorac Oncol 2009, 4(8):1035-1037.
23. Dunlap N.E., Cai J., Biedermann G.B., et al. Chest wall volume receiving>30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76(3):796-801.
24. Welsh J., Thomas J., Shah D., et al. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2011, 81(1):91-96.
25. Matsuo Y., Nakamoto Y., Nagata Y., et al. Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother Oncol 2010, 97(2):200-204.
26. Henderson M.A., Hoopes D.J., Fletcher J.W., et al. Apilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76(3):789-795.
27. Zhang X., Balter P., Pan T., et al. PET/CT and outcome in lung cancer treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010, 78(3):S16.
28. Neri S., Takahashi Y., Terashi T., et al. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers. JThorac Oncol 2010, 5(12):2003-2007.
29. Falcoz P.E., Conti M., Brouchet L., et al. The Thoracic Surgery Scoring System (Thoracoscore): risk model for in-hospital death in 15,183 patients requiring thoracic surgery. JThorac Cardiovasc Surg 2007, 133(2):325-332.
30. Chamogeorgakis T.P., Connery C.P., Bhora F., et al. Thoracoscore predicts midterm mortality in patients undergoing thoracic surgery. JThorac Cardiovasc Surg 2007, 134(4):883-887.
31. Chamogeorgakis T., Toumpoulis I., Tomos P., et al. External validation of the modified Thoracoscore in a new thoracic surgery program: prediction of in-hospital mortality. Interact Cardiovasc Thorac Surg 2009, 9(3):463-466.
32. Swanson S.J., Herndon J.E., D'Amico T.A., et al. Video-assisted thoracic surgery lobectomy: report of CALGB 39802-a prospective, multi-institution feasibility study. JClin Oncol 2007, 25(31):4993-4997.
33. Dosoretz D.E., Galmarini D., Rubenstein J.H., et al. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys 1993, 27(3):507-516.
34. Kaskowitz L., Graham M.V., Emami B., et al. Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993, 27(3):517-523.
35. Palma D., Visser O., Lagerwaard F.J., et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. JClin Oncol 2010, 28(35):5153-5159.
36. Haasbeek C.J., Palma D., Visser O., et al. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012, 23(10):2743-2747.
37. Shirvani S.M., Jiang J., Chang J.Y., et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012, 84(5):1060-1070.
38. Whitson B.A., Groth S.S., Duval S.J., et al. Surgery forearly-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg 2008, 86(6):2008-2016. [discussion: 16-8].
39. Nguyen N.P., Garland L., Welsh J., et al. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treat Rev 2008, 34(8):719-727.
40. Onishi H., Shirato H., Nagata Y., et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. JThorac Oncol 2007, 2(7 Suppl 3):S94-S100.
41. Ginsberg R., Rubinstein L. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995, 60:615-622.
42. Lagerwaard F.J., Verstegen N.E., Haasbeek C.J., et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012, 83(1):348-353.
43. Grills I.S., Mangona V.S., Welsh R., et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. JClin Oncol 2011, 28(6):928-935.
44. Crabtree T.D., Denlinger C.E., Meyers B.F., et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. JThorac Cardiovasc Surg 2010, 140(2):377-386.
45. Palma D., Visser O., Lagerwaard F.J., et al. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol 2011, 101(2):240-244.
46. Dunlap N.E., Yang W., McIntosh A., et al. Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012, 84(5):1071-1077.
47. Huang K., Dahele M., Senan S., et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)-can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 2012, 102(3):335-342.
48. Chen H.Y., Yu S.L., Chen C.H., et al. Afive-gene signature and clinical outcome in non-small-cell lung cancer. NEngl J Med 2007, 356(1):11-20.
49. Brock M.V., Hooker C.M., Ota-Machida E., et al. DNAmethylation markers and early recurrence in stage I lung cancer. NEngl J Med 2008, 358(11):1118-1128.
50. Louie A.V., Rodrigues G., Hannouf M., et al. Stereotactic body radiotherapy versus surgery for medically operable stage I non-small-cell lung cancer: a Markov model-based decision analysis. Int J Radiat Oncol Biol Phys 2011, 81(4):964-973.